arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Camp4 Therapeutics Corp

CAMP
$3.72 ▼ -0.45 (-10.79%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

Camp4 Therapeutics Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $215.5M
Dividend Yield
Revenue Growth 18.8%
Op. Margin
ROIC 1525.3%
FCF / Share $-0.22
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.78M
↑ +18.8%
Net Income Profit after all expenses
$-18.33M
↓ -47.4%
FCF / Share Free cash flow per share
$-0.22
↓ -16.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Cash Quality
35

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters